---
title: "treatment of amyloidosis"
slug: "treatment-of-amyloidosis"
date: "2023-07-21"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[amyloidosis]]

# treatment of amyloidosis

## AL, poor prognosis

- Limited involvement:
  - high-dose melphalan â†’ auto HSCT (NEJM 2007;357:1083)
- Not HSCT candidate:
  - VAD
  - dara-CyBorD :
    - [[daratumumab]] +
    - [[CYC]] + bortezomib + dexameth. (NEJM 2021;385:46).
  - [Low-dose melphalan + D] if Bor not tolerated.
- Relapse:
  - dara, ixazomib, Bor, or lenalidomide (Blood 2020;136:2620)

## AA

- Rx underlying disease. Colchicine for FMF, esp. to â†“ renal dis. ? Anti-cytokine Rx (anakinra or tocilizumab) (Clin Exp Rheumatol 2015;33:46; Amyloid 2017;24:189).

## ATTR

- Stabilize TTR tetramers: diflunisal slows neuropathy; tafamidis â†‘ QoL, â†“ CV hosp/mortality (JAMA 2013;310:2658; NEJM 2018;379:1007)
- â†“ hepatic mut TTR production: siRNA (patisiran) or anti-sense oligo (inotersen) -improve neuropathy (NEJM 2018;379:11 & 22); CRISPR in trials (NEJM 2021;385;493)
- Liver transplant can benefit some mATTR forms (Muscle Nerve 2013;47:157)
